Lumacaftor

Contraindicated

Lumacaftor Doravirine Pifeltro Reduced doravirine exposure, reduced efficacy of doravirine and an increased risk of doravirine resistance Details Lumacaftor Fostemsavir Rukobia Reduced temsavir (the active moiety of fostemsavir) exposure and possible loss of virologic response Details Lumacaftor Lenacapavir Injection Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lumacaftor Lenacapavir Oral Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Lumacaftor Lurasidone Latuda Reduced lurasidone exposure Details Lumacaftor Nifedipine Adalat® Reduced NIFEdipine exposure and reduced efficacy of NIFEdipine Details

Major

Lumacaftor Acetaminophen And Codeine Capital® & Codeine Explained Reduced codeine and morphine exposure, reduced opioid efficacy and precipitation of opioid withdrawal Details Lumacaftor Buprenorphine Belbuca Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Lumacaftor Simvastatin Flolipid Explained Reduced exposure to CYP3A substrate Details Lumacaftor Abemaciclib Verzenio Explained Decreased abemaciclib plasma concentration Details Lumacaftor Acalabrutinib Calquence Reduced acalabrutinib exposure Details Lumacaftor Alpelisib Piqray Reduced alpelisib exposure and reduced efficacy of alpelisib Details Lumacaftor Apixaban Eliquis Explained Decreased apixaban exposure Details Lumacaftor Apremilast Otezla Reduced apremilast exposure and an reduced efficacy of apremilast Details Lumacaftor Aripiprazole Injection Abilify Reduced ARIPiprazole exposure Details Lumacaftor Asciminib Scemblix Reduced asciminib exposure and reduced efficacy of asciminib Details Lumacaftor Atogepant Qulipta Reduced atogepant exposure Details Lumacaftor Avapritinib Ayvakit Reduced avapritinib exposure and reduced efficacy of avapritinib Details Lumacaftor Belumosudil Rezurock Explained Reduced belumosudil exposure and reduced efficacy of belumosudil Details Lumacaftor Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Lumacaftor Abiraterone Abirtega Reduced abiraterone exposure and reduced efficacy of abiraterone Details Lumacaftor Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Lumacaftor Amlodipine Amvaz® Reduced amLODIPine exposure Details Lumacaftor Axitinib Inlyta Reduced axitinib exposure Details Lumacaftor Bedaquiline Sirturo Reduced bedaquiline exposure and reduced efficacy of bedaquiline Details Lumacaftor Bortezomib Boruzu Reduced bortezomib exposure Details Lumacaftor Bosutinib Bosulif Reduced bosutinib exposure and reduced efficacy of bosutinib Details Lumacaftor Brexpiprazole Rexulti Reduced brexpiprazole exposure Details Lumacaftor Brigatinib Alunbrig Reduced brigatinib efficacy Details Lumacaftor Budesonide Entocort Reduced exposure to CYP3A substrate Details Lumacaftor Budesonide Nasal Spray Rhinocort Reduced exposure to CYP3A substrate Details Lumacaftor Budesonide Oral Inhalation Pulmicort Reduced exposure to CYP3A substrate Details Lumacaftor Cabozantinib Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Lumacaftor Cabozantinib (Thyroid Cancer) Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Lumacaftor Capmatinib Tabrecta Decreased capmatinib exposure and reduction of antitumor activity Details Lumacaftor Cyclosporine Injection Atopica Reduced exposure to immunosuppressant Details Lumacaftor Cyclosporine Ophthalmic Cequa Reduced exposure to immunosuppressant Details Lumacaftor Dasatinib Phyrago Reduced dasatinib exposure and reduced efficacy of dasatinib Details Lumacaftor Deflazacort Emflaza Decreased exposure to active metabolite of deflazacort Details Lumacaftor Dexamethasone Injection Decadron Reduced dexAMETHasone exposure Details